Dexcom Stock Slips 0.14% as Trading Volume Surges 71.61% to $570 Million, Climbs to No. 206 in Market Activity Amid Regulatory Delays and Medicare Uncertainty

On September 17, 2025, , , securing the stock at rank 206 in overall market activity. The move followed mixed signals from regulatory and market dynamics affecting the diabetes management sector.

Recent developments highlighted regulatory scrutiny over (CGM) device approvals, with the FDA delaying a key advisory panel meeting initially scheduled for late September. Analysts noted the postponement could impact competitive positioning in the CGM market, though no direct operational risks were flagged for Dexcom. Concurrently, a revised Medicare reimbursement framework for diabetes technologies sparked sector-wide uncertainty, though Dexcom’s pricing strategy remains insulated from immediate adjustments.

To implement an accurate back-test I need to pin down a few practical details that weren’t specified: Universe—Should we screen the whole U.S. equity universe (all NYSE/Nasdaq/AMEX listings) or a narrower list (e.g., S&P 1500, Russell 3000, etc.)? Volume definition—Rank by share volume or by dollar volume (volume × price)? Trade execution convention—Enter next-day open and exit same-day close (one trading day), or enter at today’s close and exit next-day close? Transaction costs / slippage—Assume zero, fixed bps per trade, or something else? Any risk controls (e.g., maximum capital per name, stop-loss, etc.)? Once these points are clear I’ll generate the data-retrieval plan and run the back-test.